Home > Insider Trading > Filing (0000899243-17-018010)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1420565	Aileron Therapeutics Inc	ALRN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1428044	Excel Medical Fund Lp	800 Boylston Street, Suite 2825 Boston MA 02199	No	No	Yes	No
1571997	Ph.d. R. Steven Gullans	800 Boylston Street, Suite 2825 Boston MA 02199	No	No	Yes	No
1571999	Excel Medical Ventures, Llc	800 Boylston Street, Suite 2825 Boston MA 02199	No	No	Yes	No
1572066	R. Frederick Blume	800 Boylston Street, Suite 2825 Boston MA 02199	No	No	Yes	No
1572090	Juan Enriquez	800 Boylston Street, Suite 2825 Boston MA 02199	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-07-05	956,100	$0.00	956,100	No	4	C	Direct
Common Stock	Acquisiton	2017-07-05	60,000	$15.00	1,016,100	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series D Preferred Stock	Disposition	2017-07-05	5,934,050	$0.00	597,167	$0.00
Common Stock	Series E-2 Preferred Stock	Disposition	2017-07-05	1,329,993	$0.00	133,842	$0.00
Common Stock	Series E-3 Preferred Stock	Disposition	2017-07-05	1,153,606	$0.00	116,091	$0.00
Common Stock	Series F Preferred Stock	Disposition	2017-07-05	1,083,119	$0.00	108,998	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct

Footnotes

The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
Excel Medical Ventures, LLC is the general partner of Excel Medical Fund, L.P. Steven R. Gullans, Frederick R. Blume and Juan Enriquez are the Managing Directors of Excel Medical Ventures, LLC. Excel MedicalVentures, LLC and each of these individuals may be deemed to share voting and dispositive power with respect to all shares held by Excel Medical Fund, L.P. Each of the filing persons disclaims beneficial ownership ofthe shares except to the extent of any pecuniary interest therein.